US Judge Seeks Clarity On Hegseth's Testosterone Treatment Policy For Troops
A US federal judge is questioning the Pentagon's policy on testosterone replacement therapy for troops, specifically comparing it to hormone treatments for transgender service members. The inquiry follows Defense Secretary Pete Hegseth's new initiative to screen troops for testosterone deficiency.
Why it matters
The case challenges the consistency of military medical policies and the legal framework surrounding the ban on transgender troops.
Defense Secretary Pete Hegseth's new initiative to test and treat troops for low testosterone has prompted a federal judge to question the differences between that kind of testosterone replacement therapy and hormone treatment for transgender men in the military.US District Judge Ana Reyes in Washington raised the question Wednesday in an ongoing lawsuit against President Donald Trump's ban on transgender troops. Reyes noted that Trump's ban says "the Armed Forces must adhere to high mental and physical health standards ... without the benefit of routine medical treatment or special provisions."Reyes ordered both parties in the lawsuit to address "the similarities and differences in administering TRT, both medically and logistically, for trans men compared to other service members, including cis individuals."
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in